{"nctId":"NCT02667587","briefTitle":"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","startDateStruct":{"date":"2016-05-09","type":"ACTUAL"},"conditions":["Brain Neoplasms"],"count":716,"armGroups":[{"label":"Nivolumab + Temozolomide + Radiotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Nivolumab","Drug: Temozolomide","Radiation: Radiotherapy"]},{"label":"Nivolumab placebo + Temozolomide + Radiotherapy","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Temozolomide","Radiation: Radiotherapy","Other: Nivolumab Placebo"]}],"interventions":[{"name":"Nivolumab","otherNames":["Opdivo","Nivo","N","BMS-936558"]},{"name":"Temozolomide","otherNames":["Temodar","TMZ","Temodal","Temcad"]},{"name":"Radiotherapy","otherNames":["RT"]},{"name":"Nivolumab Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Males and Females, age ≥ 18 years old\n* Newly diagnosed brain cancer or tumor called glioblastoma or GBM\n* Karnofsky performance status of ≥ 70 (able to take care of self)\n* Substantial recovery from surgery resection\n* Tumor test result shows MGMT methylated or indeterminate tumor subtype\n\nExclusion Criteria:\n\n* Biopsy-only of GBM with less than 20% of tumor removed\n* Prior treatment for GBM (other than surgical resection)\n* Any known tumor outside of the brain\n* Recurrent or secondary GBM\n* Active known or suspected autoimmune disease\n\nOther protocol defined inclusion/exclusion criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) Determined by BICR","description":"The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by a Blinded Independent Central Review (BICR) assessed based on Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.64","spread":null},{"groupId":"OG001","value":"10.32","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"The time from the date of randomization to the date of death. who have not died by the end of the study will be censored to last known date alive. OS is assessed in the randomized population with no corticosteroids at baseline population and in the overall randomized population.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.91","spread":null},{"groupId":"OG001","value":"32.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.34","spread":null},{"groupId":"OG001","value":"32.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Rates at 12 Months","description":"Overall Survival (OS) rate is defined as the percentage of participants surviving at 12 months","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Rates at 24 Months","description":"Overall Survival (OS) rate is defined as the percentage of participants surviving at 24 months","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"63.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Based on Investigator Assessment","description":"The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by investigator assessment based Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.09","spread":null},{"groupId":"OG001","value":"15.18","spread":null}]}]}]},{"type":"POST_HOC","title":"Progression-free Survival (PFS) Determined by BICR - Extended Collection","description":"The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by a Blinded Independent Central Review (BICR) assessed based on Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.89","spread":null},{"groupId":"OG001","value":"10.25","spread":null}]}]}]},{"type":"POST_HOC","title":"Overall Survival (OS) - Extended Collection","description":"The time from the date of randomization to the date of death. who have not died by the end of the study will be censored to last known date alive. OS is assessed in the randomized population with no corticosteroids at baseline population.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.94","spread":null},{"groupId":"OG001","value":"31.84","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":259,"n":355},"commonTop":["Fatigue","Nausea","Constipation","Headache","Alopecia"]}}}